Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth
@article{Petersen2004DurationOH, title={Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth}, author={Kenneth M. Petersen and Lisa R. Bulkow and Brian J. McMahon and Carolyn L Zanis and Marilyn Getty and Helen V Peters and Alan J. Parkinson}, journal={The Pediatric Infectious Disease Journal}, year={2004}, volume={23}, pages={650-655} }
Background: The duration of protection after hepatitis B vaccination of infants is unknown. Methods: We determined antibody to hepatitis B surface antigen (anti-HBs) at 4–13 years of age in 363 low risk children who had been vaccinated starting at birth with hepatitis B vaccine. Those with nonprotective titers (<10 mIU/mL) received a booster dose. We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers. Results: Of low risk infants receiving a plasma-derived…
121 Citations
Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years.
- Medicine, BiologyVaccine
- 2007
Duration of Protection After Infant Hepatitis B Vaccination Series
- MedicinePediatrics
- 2014
BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of…
Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area
- Medicine, BiologyWorld journal of pediatrics : WJP
- 2011
The data suggest that a booster dose of vaccine may be required in low HBV endemic areas and children vaccinated against HBV during infancy may show low levels of antibody during adolescence.
Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy
- MedicinePediatrics
- 2007
Although most participants responded to a booster dose of hepatitis B vaccine, the significance of the increased proportion of nonresponses among older adolescents might indicate waning immune memory.
Serum level of anti-hepatitis B surface antigen 6-8 years after hepatitis B vaccination at birth.
- Medicine, BiologyEastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
- 2008
The serum level of antibody to hepatitis B surface antigen (anti-HBsAg) in 273 randomly selected 7-9-year-old schoolchildren from Zanjan City, Islamic Republic of Iran, who had been fully vaccinated against hepatitis B starting at birth was determined.
Persistence of Antibody to Hepatitis B and Protection From Disease Among Alaska Natives Immunized at Birth
- Medicine, BiologyThe Pediatric infectious disease journal
- 2005
Anti-HBs concentrations declined over time among AN infants successfully immunized with HB vaccine starting at birth, andTransient anti-HBc appeared in a small percentage of children; however, none developed clinical signs of hepatitis or chronic HBV infection.
Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children
- MedicineEuropean Journal of Pediatrics
- 2012
It is suggested that HBV vaccination may confer long-term immunity in successfully vaccinated immunocompetent children in the region and use of routine booster doses of vaccine at these ages does not appear necessary.
Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose.
- Medicine, BiologyThe Journal of infectious diseases
- 2009
The protection afforded by primary immunization with plasma-derived hepatitis B vaccine during childhood and adulthood lasts at least 22 years, and booster doses are not needed.
Should a booster dose be administered in children after mass immunization for hepatitis B?
- MedicineHepatitis monthly
- 2011
Mass HBV vaccination, which was implemented in Turkey in 1998, significantly decreases HBsAg positivity in childhood, Nevertheless, it might be necessary to administer a booster dose after 8-9 years in children, especially those in low socioeconomic areas or in whom irregular/insufficient immunization is suspected.
Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules
- Medicine, BiologyInfection
- 2010
Delaying the first dose of the HB vaccine until 2 months after birth produces a higher immune response and can provide longer term protection, and the immunogenicity of two different HB vaccine schedules was compared.
References
SHOWING 1-10 OF 28 REFERENCES
Long‐term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen
- Medicine, BiologyHepatology
- 1999
Protection afforded by HB vaccination persisted to the age of 10 years in all vaccinees including those who had lost their anti‐HBs seropositivity, suggesting that no booster vaccination is needed before 10 years of age.
Hepatitis B vaccination in high-risk infants: 10-year follow-up.
- Medicine, BiologyThe Journal of infectious diseases
- 1999
Because the level of antibody persistence remained high and few became carriers, booster revaccination within 10 years seems unnecessary.
Increases in levels of antibody to hepatitis B surface antigen in an immunized population.
- Biology, MedicineClinical infectious diseases : an official publication of the Infectious Diseases Society of America
- 1998
The results underscore the continued exposure to HBV among vaccinees and the continued protection against disease that the vaccine provides.
Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years.
- Biology, MedicineVaccine
- 1996
Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine.
- Medicine, BiologyResearch in virology
- 1997
Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study.
- Medicine, BiologyThe Journal of infectious diseases
- 1997
It is suggested that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.
Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity.
- Medicine, BiologyVaccine
- 1997
Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program.
- MedicineThe Journal of infectious diseases
- 2000
A hepatitis B immunization program that includes prevention of perinatal HBV infection, routine infant vaccination, and catch-up vaccination of older children and adults can eliminate new chronic HBV infections in a population with a high rate of chronic infection.
Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population.
- Medicine, BiologyJAMA
- 1989
In 1981, a hepatitis B virus vaccine demonstration project was conducted in 1630 Yupik Eskimos in southwest Alaska, and in the 5 years following the demonstration project, the annual incidence of hepatitis Birus infection decreased from 50 cases per 1000 population before the vaccine trial to 0.45 per 1000.
Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series.
- Medicine, BiologyJAMA
- 2000
Administration of the first dose of hepatitis B vaccine at birth is associated with increased likelihood of completion of the hepatitis B vaccination series.